Bausch + Lomb pushes dry eye therapy to Phase 3 after Phase 2 miss
Bausch + Lomb disclosed that its dual-action dry eye drop failed to meet its primary endpoint in a Phase 2 study. Despite the setback, CEO Brent Saunders expressed optimism about the results, calling them a better outcome than anticipated. The company intends to advance the candidate into a Phase 3 trial.
Related stories
Spyre halts RA program for anti-TL1A candidate after Phase 2 disappointment · Drug development
Argenx's subcutaneous therapy meets late-stage goal in rare muscle disease, with subgroup miss · Drug development
Personalized mRNA vaccine hits Phase 3 goal in Merck-Moderna trial · Cancer research
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “Bausch + Lomb plans Ph3 trial for dry eye drop, despite missing mid-stage goal.” Browse more stories.